Fig 1: Role for T-cell immunity in virus-mediated tumor clearance. a Schematic representation of T-cell depletion study. b Confirmation of T-cell depletion by IP anti-CD4, anti-CD8, or isotype treatment 24 h prior to harvesting. Splenocytes were isolated 24 h after IP administration of anti-T-cell depletion antibodies in naïve FVB/N mice, and probed for CD3 + , CD4 + , and CD8 + T-cells as measured by flow cytometry. Live spenocytes were gated using forward and side scatter, and then gated on CD4-FITC and CD8-PE. Single-color positive quadrants (Q1 for CD8 + and Q3 for CD4 + ) were interrogated to determine depletion. c Survival of DB7 tumor-bearing FVB/N mice treated with saline control or HSV-P10 7 days post tumor cell implantation, and isotype or anti-CD4 antibodies 2, 4, and 7 days post virus injection. Significance in survival was assessed by Logrank (Mantel–Cox) test (n = 10, **p < 0.01). d Survival of DB7 tumor-bearing FVB/N mice treated with saline control or HSV-P10 7 days post tumor cell implantation, and isotype or anti-CD8 antibodies 2, 4, and 7 days post virus injection as indicated. Significance in survival was assessed by Logrank (Mantel–Cox) test (n = 10, **p < 0.01). e 51Cr release from uninfected DB7 tumor cells co-cultured with CD3 + splenocytes from untreated naive or immune mice from Fig. 5d. Data shown are averages ± s.d. Statistical significance was assessed by one-tailed Student’s T-test (n = 3, *p < 0.05)